RXRX
Recursion Pharmaceuticals Inc
3.70$
-8.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.1% | 67.0% | 61.6% | 67.3% | 65.3% | 49.3% | 44.8% | 45.1% | 51.0% | 55.1% | 53.0% | 49.8% | |
| 61.4% | 59.9% | 53.7% | 61.1% | 58.9% | 41.0% | 38.3% | 40.6% | 47.1% | 50.4% | 48.9% | 45.0% | |
| 61.4% | 59.9% | 53.7% | 61.1% | 58.9% | 41.0% | 38.3% | 40.6% | 47.1% | 50.4% | 48.9% | 45.0% | |
| 0.5% | 0.5% | 0.5% | 0.3% | 0.3% | 3.4% | 3.5% | 1.7% | 1.6% | 1.7% | 1.0% | 1.2% | |
| 0.4% | – | – | – | – | – | – | – | – | – | – | – | |
| 8.4% | 8.0% | 9.3% | 6.7% | 7.2% | 10.3% | 12.1% | 12.6% | 11.6% | 11.0% | 12.0% | 13.2% | |
| 6.3% | 5.6% | 5.9% | 4.9% | 4.7% | 23.2% | 25.7% | 26.2% | 23.0% | 21.0% | 22.0% | 23.3% | |
| 30.6% | 29.1% | 28.1% | 24.7% | 27.8% | 28.6% | 28.4% | 29.4% | 25.2% | 23.3% | 23.5% | 24.5% | |
| 14.9% | 14.3% | 13.3% | 11.1% | 15.0% | 12.9% | 10.9% | 12.6% | 11.1% | 10.0% | 9.7% | 9.9% | |
| 1.0% | 0.9% | 1.1% | 2.2% | 2.3% | 1.5% | 1.6% | 1.6% | 1.5% | 1.5% | 1.7% | 1.9% | |
| 0.7% | 0.6% | 0.9% | 0.5% | 0.3% | 1.5% | 1.9% | 1.5% | 1.0% | 1.2% | 1.5% | 1.0% | |
| 0.2% | 0.2% | 0.2% | 3.0% | 2.8% | 1.3% | 1.3% | 1.1% | 0.9% | 0.6% | 0.5% | 0.4% | |
| 69.4% | 70.9% | 71.9% | 75.3% | 72.2% | 71.4% | 71.6% | 70.6% | 74.8% | 76.7% | 76.5% | 75.5% | |
| -138.6% | -148.0% | -189.8% | -149.1% | -172.4% | -98.8% | -125.2% | -138.6% | -140.6% | -140.8% | -163.8% | -191.7% | |
| 34.0% | 35.7% | 42.3% | 31.2% | 38.9% | 23.2% | 30.9% | 32.0% | 31.9% | 35.7% | 39.5% | 43.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.